Rate Video

ASH 2018 | CLL trial updates: ALLIANCE & iLLUMINATE

Barbara Eichhorst

ASH 2018

Chronic Lymphocytic Leukemia Leukemia Bendamustine Ibrutinib Obinutuzumab Rituximab

ALLIANCE A041202 iLLUMINATE

Barbara Eichhorst, MD, of the University Hospital Cologne, Cologne, Germany, discusses the results of major chronic lymphocytic leukemia (CLL) trials from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA. Dr Eichhorst then summarizes what the implications of these trials are in terms of the use of ibrutinib.

Treating CLL with venetoclax

Barbara Eichhorst • 9 Jun 2016

Novel agents in CLL: acalabrutinib and zanubrutinib

Barbara Eichhorst

How to treat eldery CLL patients

Barbara Eichhorst • 9 Jun 2016

Pirtobrutinib: The next generation of BTK inhibitors

Barbara Eichhorst • 8 Jun 2021

Related Videos

Key challenges of using the intestinal microbiome as a biomarker

CAR T-cell therapy: the importance of LTFU

The future of AML therapy

Andreas Burchert

Treating pediatric patients with hematological malignancies

Claudia Rössig